!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! NEWS !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1
Fobi Announces The Commercial Launch Of PulseIR With First Client, Digital Health Platform PanGenomic Health Inc.
8:00 AM ET 1/30/23 | GlobeNewswire
Fobi Announces The Commercial Launch Of PulseIR With First Client, Digital Health Platform PanGenomic Health Inc.
VANCOUVER, BC, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, is pleased to announce the commercial launch of its wholly-owned subsidiary, PulseIR, with the signing of its first customer, PanGenomic Health Inc. PanGenomic offers a self-care digital platform to deliver personalized, evidence-based information about natural and plant-based health treatments. PulseIR is a platform as a service (PaaS) and will generate revenue through an annual license and initial setup fee.
Investor relations (IR) platforms have traditionally lacked the level of sophistication and mobilization that every early-stage company needs to connect their stories, drive ROI, and gain traction in a market that's now entirely digital. With an opportunity to revolutionize the world of investor relations, PulseIR, which supports Fobi's IR platform Investor Pass, delivers a whole new experience of personalized engagement through real-time, mobile lock screen communication. PulseIR brings a data-driven and digital approach to IR right into the palms of today's new-age investors, generating a new sense of urgency that provides shareholders with a direct understanding of price action, volume alerts, company news, events, and more.
PulseIR's go-to-market launch with PanGenomic Health Inc. signifies a milestone growth opportunity as companies across industries look to connect and enhance their existing marketing infrastructure through automation.
Rob Anson, CEO of Fobi, states: "There's no arguing that the world has experienced a major shift towards data-first digital transformation over the last few years. With the launch of PulseIR, we're providing companies like PanGenomic with the automated tools to deliver a mobilized, data-driven activation and communications channel for investor relations."
The Company has granted, pursuant to its Stock Option Plan ("Plan") an aggregate of 3,814,892 stock options("Options") to several Company employees and officers to purchase an aggregate of up to 3,814,892 common shares ("Shares") in the capital of the Company. In part, the Options are part of contractual obligations to certain employees and the Company uses them as part of its strategy to incentivize and retain a strong team that will drive the Company's growth. The Options were awarded at an exercise price of $0.325 per Share, vest immediately and expire five years from the grant date.
For more information on PulseIR please visit www.pulseir.com.
This press release is available on the Fobi website.
AI
